Pediatric Tumors Carry Higher NTRK Mutation Burden Than Adult Tumors
Investigators assessed the frequency, fusion partners, and clinical course in pediatric patients with NTRK fusion–positive tumors.
Investigators assessed the frequency, fusion partners, and clinical course in pediatric patients with NTRK fusion–positive tumors.
Population-based study evaluated survival outcomes for patients with cancer diagnosed over a 41-year period.
This fact sheet provides suggestions for parents to help their children with cancer cope with some common side effects of anticancer treatment.
Cancer incidence trends across 41 countries demonstrated sharp increases and decreases in certain cancer types over the last 15 years.
Survival from time of recurrence was similar to that seen in younger patients.
Pediatric medulloblastoma demonstrated a distinct methylation profile that could identify the disease and monitor treatment response.
As part of the Zero Childhood Cancer Program, high-risk pediatric tumors were characterized by whole-genome sequencing, RNA sequencing, and methylation profiling.
The prospective study showed that after 4 years, complete resection of the tumor for children with local lymph node involvement (no metastasis) delivered an overall survival rate of 91.4%.
The FDA and EMA expressed the need for trial sponsors to coordinate their submissions of initial pediatric study plans and pediatric investigation plans for new oncology drugs.
2007 to 2016 saw increase in overall cancer incidence in all age groups, mainly driven by thyroid cancer.